A phase 2, open-label, single arm trial to evaluate the shedding and safety of CAIV-T administered to children 6 to less than 60 months of age.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors MedImmune
- 29 Oct 2010 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 29 Oct 2010 Additional lead trial investigator (Raburn Mallory) identified as reported by ClinicalTrials.gov.
- 05 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.